SCHEMBL59765

SCHEMBL59765

CN1CCc2cccc3c2C1Cc1ccccc1-3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 11/20 1.00
HTR1A P08908 8/20 1.00
HTR2A P28223 3/20 0.72
HTR7 P34969 2/20 0.72
DRD1 P21728 2/20 0.69
HTR6 P50406 1/20 0.68
KDM4E B2RXH2 2/20 0.64
MEN1 O00255 2/20 0.64
ALDH1A1 P00352 2/20 0.64
TP53 P04637 2/20 0.64
CYP1A2 P05177 2/20 0.64
CYP3A4 P08684 2/20 0.64
MAPT P10636 2/20 0.64
CYP2C9 P11712 2/20 0.64
PKM P14618 2/20 0.64
HPGD P15428 2/20 0.64
MAPK1 P28482 2/20 0.64
MDM2 Q00987 2/20 0.64
KMT2A Q03164 2/20 0.64
HSD17B10 Q99714 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31079473 1.00 DRD2 (1.00) DRD2HTR1AHTR2AHTR7DRD1
SCHEMBL31029854 1.00 DRD2 (1.00) DRD2HTR1AHTR2AHTR7DRD1
SCHEMBL25173335 1.00 DRD2 (1.00) DRD2HTR1AHTR2AHTR7DRD1
SCHEMBL29723260 1.00 DRD2 (1.00) DRD2HTR1AHTR2AHTR7DRD1
Bromide SCHEMBL11710282 0.98 DRD2 (0.97) DRD2HTR1AHTR2AHTR7DRD1
Hydrochloric Acid SCHEMBL11707353 0.98 DRD2 (0.97) DRD2HTR1AHTR2AHTR7DRD1
SCHEMBL28809991 0.98 DRD2 (0.97) DRD2HTR1AHTR2AHTR7DRD1
Trifluoromethanesulfonic Acid SCHEMBL1203844 0.85 DRD2 (0.73) DRD2HTR1AHTR2AHTR7DRD1
Isoquinoline SCHEMBL28350142 0.84 DRD2 (0.71) DRD2HTR1AHTR2AHTR7DRD1
SCHEMBL15847729 0.84 DRD2 (0.72) DRD2HTR1AHTR2AHTR7DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115925626-B Novel aporphine compound and preparation method and application thereof 中国药科大学 2025-06-13 CN claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
CN-119588950-A Preparation method of metal organic coordination polymer mediated silver nanowire 深圳市源利电子新材料有限公司 2025-03-11 CN claimed
CN-119000838-A Computer-aided isoquinoline alkaloid diagnostic ion acquisition method 中国科学院大连化学物理研究所 2024-11-22 CN claimed
CN-118703454-A Cytochrome P450 enzyme from stephania tetrandra and application thereof in biosynthesis of aporphine alkaloid compound 中国中医科学院中药研究所 2024-09-27 CN claimed
US-20240299481-A1 STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION SAWAI PHARMACEUTICAL CO., LTD. (JP) 2024-09-12 US claimed
CN-118146156-A Aporphine alkaloid compound, preparation method and application thereof, and pharmaceutical composition 中国科学院大连化学物理研究所 2024-06-07 CN claimed
CN-114891840-B Lotus leaf O-methyltransferase and application of encoding gene thereof in synthesis of benzyl isoquinoline alkaloid and phenylpropionic acid compounds 中国中医科学院中药研究所 2024-04-30 CN claimed
CN-115490637-B Preparation method and application of aporphine alkaloid compound 海南医学院 2024-03-29 CN claimed
US-20240102061-A1 METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES HERCULES CAPITAL, INC., AS AGENT 2024-03-28 US claimed
EP-1309553-A1 NEW APORPHINE ESTERS AND THEIR USE IN THERAPY Axon Biochemicals B.V. (NL) 2003-05-14 EP claimed
WO-2002100377-A1 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF AXON BIOCHEMICALS B.V (NL) 2002-12-19 WO claimed
WO-2002014279-A1 NEW APORPHINE ESTERS AND THEIR USE IN THERAPY AXON BIOCHEMICALS B.V. (NL) 2002-02-21 WO claimed
US-20010000731-A1 Method for the prevention and treatment of chronic venous insufficiency UNIGEN PHARMACEUTICALS, INC. 2001-05-03 US claimed
US-6210680-B1 ADMINISTRATION TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF AN ISOQUINOLINE ALKALOID. UNIVERA PHARMACEUTICALS, INC. 2001-04-03 US claimed
WO-2000076526-A1 METHOD FOR THE PREVENTION AND TREATMENT OF CHRONIC VENOUS INSUFFICIENCY UNIVERA PHARMACEUTICALS, INC. (US) 2000-12-21 WO claimed
US-6126924-A Light responsive self-tanning products and methods for use SCALES-MEDEIROS VIRGINIA A (US) 2000-10-03 US claimed
US-5156847-A Aporphinoid alkaloid in nonaqueous solvent Lewis, Walter H. (US) 1992-10-20 US claimed
WO-1990012574-A1 DOPAMINE AGONIST COMPOUNDS NORTHEASTERN UNIVERSITY (US) 1990-11-01 WO claimed
US-4013664-A PSCHORR CYCLIZATION RESEARCH CORPORATION (US) 1977-03-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299481-A1 STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION SARS1, BCDIN3D, CCL5 DRD2 2333/4885HTR1A 1355/4885HTR2A 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.